高危血液恶性肿瘤成人单倍体造血细胞移植中个体化兔抗胸腺细胞球蛋白给药:暴露-反应分析与群体药代动力学模拟
该回顾性研究分析103例接受减低强度单倍体造血细胞移植的高危血液恶性肿瘤患者,发现移植第0天兔抗胸腺细胞球蛋白浓度(Cday_0)是100天内2-4级急性移植物抗宿主病的最强预测因子。Cday_0≥20 μg/mL者2-4级和3-4级急性移植物抗宿主病风险约低3倍,总体死亡率和复发风险约低2倍。作者据此利用既往群体药代动力学模型开发了个体化给药方案,并认为该方案需前瞻性验证。
要点
- 移植第0天兔抗胸腺细胞球蛋白浓度是100天内2-4级急性移植物抗宿主病的最强预测因子。
- Cday_0≥20 μg/mL者2-4级急性移植物抗宿主病风险约低3倍(HR 0.32)。
- 该减低强度单倍体移植联合暴露优化兔抗胸腺细胞球蛋白可能为高危移植患者提供有前景的选择。
核心结论
- 该减低强度单倍体造血细胞移植方案联合暴露优化的兔抗胸腺细胞球蛋白可能为接受高危造血细胞移植的血液恶性肿瘤患者提供有前景的选择。
- 所开发的兔抗胸腺细胞球蛋白给药方案需前瞻性验证。
研究设计与样本
- 回顾性分析103例接受单倍体减低强度造血细胞移植的血液恶性肿瘤患者,中位年龄47岁(范围17-70岁),88%移植前疾病未缓解。
- 利用既往开发的群体药代动力学模型,开发个体化兔抗胸腺细胞球蛋白给药以优化暴露。
主要发现
- 移植第0天兔抗胸腺细胞球蛋白浓度是100天内2-4级急性移植物抗宿主病的最强预测因子。
- Cday_0≥20 μg/mL者2-4级急性移植物抗宿主病风险约低3倍(HR 0.32,95%CI 0.16-0.62),3-4级急性移植物抗宿主病风险约低3倍(HR 0.33,95%CI 0.16-0.68)。
- Cday_0≥20 μg/mL者总体死亡率风险约低2倍(HR 0.47,95%CI 0.28-0.77),复发风险约低2倍(HR 0.50,95%CI 0.26-0.94)。
关键数值与推荐
- Cday_0≥20 μg/mL者2-4级急性移植物抗宿主病HR 0.32(95%CI 0.16-0.62),3-4级急性移植物抗宿主病HR 0.33(95%CI 0.16-0.68)。
- Cday_0≥20 μg/mL者总体死亡率HR 0.47(95%CI 0.28-0.77),复发HR 0.50(95%CI 0.26-0.94)。
临床怎么用
- 作者认为,该减低强度单倍体移植方案联合暴露优化兔抗胸腺细胞球蛋白可能为高危移植患者提供有前景的选择。
- 作者指出,所开发的兔抗胸腺细胞球蛋白给药方案需前瞻性验证。
局限性
- 原文为回顾性分析。
- 所开发的兔抗胸腺细胞球蛋白给药方案需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hematopoietic cell transplantation (HCT) for hematologic malignancies with non-remission disease and/or prior post-transplant relapse have poor relapse-free survival. We previously demonstrated the efficacy of haploidentical reduced-intensity HCT regimen with glucocorticoid-based graft-versus-host disease (GVHD) prophylaxis. We recently showed a possible association between rabbit antithymocyte globulin (rATG) exposure and acute GVHD (aGVHD) risk, leading to hypothesize that optimization of rATG exposure may further improve this regimen. We retrospectively examined the exposure-response association of rATG and key clinical outcomes post haploidentical HCT. We subsequently developed an individualized rATG dosing that optimizes rATG exposure using a previously developed population pharmacokinetic model. Of the 103 patients analyzed, the median age was 47 years (range: 17-70) and majority had a non-remission disease prior to HCT (88%). rATG concentration on day 0 of HCT (Cday_0 ) was the strongest predictor of Grade 2-4 aGVHD through day +100. Patients with Cday_0 ≥ 20 μg/mL had an approximately 3-fold lower risk of Grade 2-4 aGVHD (hazard ratio [HR]: 0.32, 95% confidence interval [CI]: 0.16, 0.62) and Grade 3-4 aGVHD (HR: 0.33, 95% CI: 0.16, 0.68) as well as an approximately 2-fold lower risk of overall mortality (HR: 0.47, 95% CI: 0.28, 0.77) and relapse (HR: 0.50, 95% CI: 0.26, 0.94). In conclusion, this reduced-intensity haploidentical HCT regimen with exposure-optimized rATG may provide a promising option to patients undergoing high-risk HCT for hematologic malignancy. The developed rATG dosing warrant prospective validation.
引用
- Teramoto M, Takahashi T, Matsumoto K, et al. Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: Exposure-response analysis and population pharmacokinetics simulations. Am J Hematol. 2024. PMID: 38165019. doi:10.1002/ajh.27195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。